Skip to main content
SpringerLink
Log in

Sorafenib not a cost-effective treatment option in locally advanced hepatocellular carcinoma

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. SorAfenib versus Radioembolization in Advanced HCC

  2. Selective Internal Radiation Therapy Versus Sorafenib in Locally Advanced HCC

Reference

  • Marqueen KE, et al. Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma. JCO Oncology Practice : OP2000443, 8 Jan 2021. Available from: URL: http://doi.org/10.1200/OP.20.00443

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sorafenib not a cost-effective treatment option in locally advanced hepatocellular carcinoma. PharmacoEcon Outcomes News 870, 29 (2021). https://doi.org/10.1007/s40274-021-7432-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7432-6

Search

Navigation